1. Home
  2. ANVS vs IMAB Comparison

ANVS vs IMAB Comparison

Compare ANVS & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ANVS
  • IMAB
  • Stock Information
  • Founded
  • ANVS 2008
  • IMAB 2014
  • Country
  • ANVS United States
  • IMAB United States
  • Employees
  • ANVS N/A
  • IMAB N/A
  • Industry
  • ANVS Biotechnology: Pharmaceutical Preparations
  • IMAB Biotechnology: Pharmaceutical Preparations
  • Sector
  • ANVS Health Care
  • IMAB Health Care
  • Exchange
  • ANVS Nasdaq
  • IMAB Nasdaq
  • Market Cap
  • ANVS 92.6M
  • IMAB 87.2M
  • IPO Year
  • ANVS 2020
  • IMAB 2020
  • Fundamental
  • Price
  • ANVS $2.95
  • IMAB $0.99
  • Analyst Decision
  • ANVS Strong Buy
  • IMAB Strong Buy
  • Analyst Count
  • ANVS 6
  • IMAB 3
  • Target Price
  • ANVS $29.67
  • IMAB $8.00
  • AVG Volume (30 Days)
  • ANVS 535.2K
  • IMAB 270.7K
  • Earning Date
  • ANVS 03-31-2025
  • IMAB 03-13-2025
  • Dividend Yield
  • ANVS N/A
  • IMAB N/A
  • EPS Growth
  • ANVS N/A
  • IMAB N/A
  • EPS
  • ANVS N/A
  • IMAB N/A
  • Revenue
  • ANVS N/A
  • IMAB $3,313,984.00
  • Revenue This Year
  • ANVS N/A
  • IMAB N/A
  • Revenue Next Year
  • ANVS N/A
  • IMAB N/A
  • P/E Ratio
  • ANVS N/A
  • IMAB N/A
  • Revenue Growth
  • ANVS N/A
  • IMAB N/A
  • 52 Week Low
  • ANVS $2.88
  • IMAB $0.84
  • 52 Week High
  • ANVS $20.00
  • IMAB $2.00
  • Technical
  • Relative Strength Index (RSI)
  • ANVS 20.82
  • IMAB 43.19
  • Support Level
  • ANVS $2.99
  • IMAB $1.03
  • Resistance Level
  • ANVS $5.50
  • IMAB $1.10
  • Average True Range (ATR)
  • ANVS 0.34
  • IMAB 0.06
  • MACD
  • ANVS -0.18
  • IMAB -0.01
  • Stochastic Oscillator
  • ANVS 3.59
  • IMAB 7.58

About ANVS Annovis Bio Inc.

Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.

About IMAB I-MAB

I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).

Share on Social Networks: